Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Ophiopogonin-D

Copy Product Info
🥰Excellent
Catalog No. T6S1255Cas No. 41753-55-3

Ophiopogonin-D significantly inhibited the in vitro and in vivo growth of prostate cells via RIPK1. Ophiopogonin-D may be developed as a potential anti-prostate cancer agent.

Ophiopogonin-D

Ophiopogonin-D

Copy Product Info
🥰Excellent
Purity: 97.16%
Catalog No. T6S1255Cas No. 41753-55-3
Ophiopogonin-D significantly inhibited the in vitro and in vivo growth of prostate cells via RIPK1. Ophiopogonin-D may be developed as a potential anti-prostate cancer agent.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$64In StockIn Stock
5 mg$158In StockIn Stock
10 mg$213In StockIn Stock
25 mg$359In StockIn Stock
50 mg$532In StockIn Stock
100 mg$757In StockIn Stock
1 mL x 10 mM (in DMSO)$196In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:97.16%
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Ophiopogonin-D significantly inhibited the in vitro and in vivo growth of prostate cells via RIPK1. Ophiopogonin-D may be developed as a potential anti-prostate cancer agent.
In vitro
Ophiopogonin D(OPD) was shown to exert potent anti-tumor activity against PC3 cells.?It induced apoptosis via a RIPK1-related pathway, increased the protein expression levels of RIPK1 and Bim, and decreased the levels of cleaved-RIPK1, caspase 8, cleaved-caspase 8, Bid, caspase 10, and cleaved-caspase 10.?OPD' also increased the mRNA expression of Bim.?The protein expression of Bim was decreased when cells were pre-treated with necrostatin-1[1].
In vivo
Ophiopogonin D(OPD)′ treatment led to significant tumor growth inhibition at a dose of 5.0 mg/kg bodyweight, beginning on Day 6 of treatment (p = 0.034).?At the end of the study (Day 24), the tumor tissues were excised, photographed, and weighed.?Treatment with 5.0 mg/kg bodyweight OPD′ resulted in significant (p = 0.000) tumor growth inhibition by approximately 79.8% on Day 24 compared to the vehicle treatment.?The 5.0 mg/kg dose led to significantly stronger tumor growth inhibition than the 2.5 mg/kg dose (p = 0.000).?There was not a significant loss of body weight in any of the groups[1].
Cell Research
The CCK-8 assay was used to assess the viability of prostate cancer cells.?The cell morphology was examined by an ultrastructural analysis via transmission electron microscopy.?Cells in apoptosis (early and late stages) were detected using an Annexin V-FITC/propidium iodide kit with a FACSCaliber flow cytometer.?JC-1, a cationic lipophilic probe, was employed to measure the mitochondrial membrane potential (MMP) of PC3 cells.?Changes in the protein expression of RIPK1, C-RIPK1, caspase 8, cleaved-caspase 8, Bim, Bid, caspase 10, and cleaved-caspase 10 were evaluated by Western blotting.?The mRNA expression of Bim was examined by quantitative real-time reverse transcription polymerase chain reaction.?Z-VAD-FMK (a caspase inhibitor) and necrostatin-1 (a specific inhibitor of RIPK1) were utilized to determine whether the cell death was mediated by RIPK1 or caspases[1].
Animal Research
One week after tumor cell inoculation, mice bearing palpable tumors were randomly divided into control and treatment groups (8 mice/group).?OPD′ was dissolved in the vehicle, PEG400:Saline:Ethanol (400:300:200, v/v/v), and administered (via i.p. injection) at doses of 2.5 or 5.0 mg/kg bodyweight 5 days a week for 24 days.?The control group received vehicle only.?The mice were sacrificed by cervical dislocation on Day 24, and the tumor tissues were removed and weighed[1].
Chemical Properties
Molecular Weight855.02
FormulaC44H70O16
Cas No.41753-55-3
SmilesC[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)C[C@@H](O[C@@H]6O[C@H](C)[C@H](O)[C@H](O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O[C@@H]6O[C@@H](C)[C@H](O)[C@@H](O)[C@H]6O)[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1
Relative Density.1.42 g/cm3
Storage & Solubility Information
Storagekeep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 30 mg/mL (35.09 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.1696 mL5.8478 mL11.6956 mL58.4782 mL
5 mM0.2339 mL1.1696 mL2.3391 mL11.6956 mL
10 mM0.1170 mL0.5848 mL1.1696 mL5.8478 mL
20 mM0.0585 mL0.2924 mL0.5848 mL2.9239 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Ophiopogonin-D | purchase Ophiopogonin-D | Ophiopogonin-D cost | order Ophiopogonin-D | Ophiopogonin-D chemical structure | Ophiopogonin-D in vivo | Ophiopogonin-D in vitro | Ophiopogonin-D formula | Ophiopogonin-D molecular weight